Clinical Trial

Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study

Study acronym: REIN-TEP PSMA
Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Due to administrative issues, the study was abandoned before recruitment began.
Summary
Kidney cancer in adults is the seventh leading cause of cancer-related death in France. Early and accurate imaging of the primary tumour and the identification of metastatic sites are major prognostic factors that are crucial for determining the appropriate stage-specific treatment. However, the diagnosis of sub-centimetre metastatic lymph nodes and occult metastatic lesions remains difficult with current imaging methods. Recent publications have shown promising results for 68Ga-PSMA PET-CT in the detection of metastases from renal cell carcinoma (RCC). It is therefore necessary to develop a new, more sensitive and specific imaging method to detect occult metastatic foci, enabling the earlier initiation of specific systemic or local treatment, and thereby improving survival in these patients or even achieving prolonged remission in oligometastatic cases Experience and acceptability of a new organisational model in primary care: participatory multi-professional health centres
Trial Details
NCT Number NCT07624578
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Kidney Cancers
Start Date 2020-01
Primary Completion 2022-02 (estimated)
Study Completion 2022-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-03